Deferasirox Supplier in Qatar
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer to MOPH-QA-registered importers.
Supply & Market
Taj Pharma supplies WHO-GMP Deferasirox dispersible tablets to Qatar through Gulf-region wholesalers, hospital pharmacies and Ministry-of-Health tenders. Shipments to Taj Pharma India Ltd. arrive via Jebel Ali, Dammam, Aqaba and Beirut, with full Arabic / English secondary-pack labelling on request.
The Qatar market for iron-chelation therapy is driven by a high regional prevalence of thalassemia and other transfusion-dependent anaemias, where Deferasirox is the preferred once-daily oral chelator.
Our regulatory and commercial team in Mumbai partners directly with importers, hospital procurement officers and Ministry-of-Health tender desks across Qatar — from Doha to regional referral centres — for streamlined supply continuity.
Supply Capability for Qatar
DEFRATAJ is supplied to Qatar across all five strengths — 100 mg, 125 mg, 250 mg, 400 mg and 500 mg dispersible tablets — in HDPE bottles (30s/60s/100s) and Alu-Alu blister packs. Minimum-order quantities start at 50,000 tablets per strength with a typical lead time of 4–6 weeks from PO confirmation.
- Strengths shipped: 100 mg, 125 mg, 250 mg, 400 mg, 500 mg dispersible tablets
- Pack sizes: bottles (30/60/100 tabs), Alu-Alu blisters (10x10), hospital institutional packs
- MOQ: 50,000 tablets per strength per shipment (mixed pallets supported)
- Lead time: 4–6 weeks ex-Mumbai (JNPT / Nhava Sheva)
- Shelf life: 24 months at 25°C / 60% RH (Zone IVb stability data on file)
- Documents per shipment: CoA, CoO, packing list, invoice, BL/AWB, free-sale certificate
- Private label / co-branding: available with own artwork and brand registration
Cold-chain is not required for dispersible tablets, but climatised containers can be arranged on request for hot-route lanes into Qatar.
Regulatory Pathway in Qatar
Deferasirox dispersible tablets are registered in Qatar with the Ministry of Public Health Qatar (MOPH-QA). Taj Pharma submits the full CTD dossier (Modules 1–5) along with our WHO-GMP certificate, CoPP, manufacturing licence, plant master file and validated stability data to MOPH-QA. Our regulatory desk handles queries, sample submissions and post-approval variations on behalf of local marketing-authorisation holders.
Local agent appointment, secondary packaging in Arabic, and pharmacovigilance reporting are all coordinated from our Mumbai head office. Documentation can be couriered or e-submitted to MOPH-QA in Doha.
- CTD dossier (Modules 1–5) ready
- WHO-GMP · ISO 9001 · PIC/S-aligned plant
- CoPP & manufacturing licence on request
- Stability data (long-term & accelerated, Zone IVb)
- Country code
QA· trade currency Qatari Riyal